Theradiag SA Market Cap ($36.75 Million)
Market Cap & Net Worth: Theradiag SA (ALTHE)
Theradiag SA market cap. Theradiag SA (PA:ALTHE) has a market capitalization of $36.75 Million (€31.43 Million) as of November 7, 2026. Listed on the PA stock exchange, this France-based company holds position #22772 globally and #356 in its home market, demonstrating a -5.27% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Theradiag SA's stock price €0.70 by its total outstanding shares 59081130 (59.08 Million). Also see how efficiently does Theradiag SA generate cash for how efficiently the company converts equity into cash flow.
Theradiag SA Market Cap History (2015–2026)
Theradiag SA market cap history from 2015 to 2026. Data shows change from $434.76 Million to $48.42 Million (-19.94% CAGR). Check Theradiag SA stock price for real-time trading data and today's change.
Theradiag SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Theradiag SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ALTHE shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
27.55x
Theradiag SA's market cap is 27.55 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $434.76 Million | $1.60 Million | -$6.41 Million | 272.16x | N/A |
| 2016 | $361.25 Million | $1.98 Million | -$6.54 Million | 182.91x | N/A |
| 2017 | $282.50 Million | $2.82 Million | -$6.22 Million | 100.03x | N/A |
| 2018 | $46.28 Million | $1.94 Million | -$6.14 Million | 23.86x | N/A |
| 2019 | $113.97 Million | $2.78 Million | -$3.79 Million | 40.94x | N/A |
| 2020 | $139.53 Million | $744.00K | -$3.90 Million | 187.53x | N/A |
| 2021 | $90.48 Million | $1.48 Million | -$3.76 Million | 61.10x | N/A |
| 2022 | $62.44 Million | $1.24 Million | -$4.96 Million | 50.54x | N/A |
| 2023 | $26.80 Million | $1.82 Million | -$3.68 Million | 14.71x | N/A |
| 2024 | $22.86 Million | $830.00K | -$5.76 Million | 27.55x | N/A |
Competitor Companies of ALTHE by Market Capitalization
Companies near Theradiag SA in the global market cap rankings as of November 7, 2026. Also see Theradiag SA balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Theradiag SA by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #109 globally with a market cap of $191.15 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #188 globally with a market cap of $124.99 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #222 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #233 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #109 | Abbott Laboratories | NYSE:ABT | $191.15 Billion | $109.93 |
| #188 | Stryker Corporation | NYSE:SYK | $124.99 Billion | $325.87 |
| #222 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $101.80 |
| #233 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Theradiag SA (2015–2026)
Market capitalization of Theradiag SA from 2015 to today. Between 2015 and today, Theradiag SA's market cap moved from $434.76 Million to $ 48.42 Million, with a yearly change of -19.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €48.42 Million | +16.45% |
| 2025 | €41.58 Million | +81.87% |
| 2024 | €22.86 Million | -14.69% |
| 2023 | €26.80 Million | -57.08% |
| 2022 | €62.44 Million | -30.99% |
| 2021 | €90.48 Million | -35.15% |
| 2020 | €139.53 Million | +22.42% |
| 2019 | €113.97 Million | +146.27% |
| 2018 | €46.28 Million | -83.62% |
| 2017 | €282.50 Million | -21.80% |
| 2016 | €361.25 Million | -16.91% |
| 2015 | €434.76 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Theradiag SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $36.75 Million USD |
| MoneyControl | $36.75 Million USD |
| MarketWatch | $36.75 Million USD |
| marketcap.company | $36.75 Million USD |
| Reuters | $36.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Theradiag SA
Theraclion SA provides therapeutic ultrasound equipment. It offers SONOVEIN, a robotic solution for the non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for the echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment to protect the patient's skin and optimize imag… Read more